| Press Release Source:
eFoodSafety.com, Inc.
eFoodSafety Provides
Product Update
Tuesday May 13, 9:30
am ET
Offerings Available Across Several
Distribution Channels, Others in the Pipeline
SCOTTSDALE, Ariz.--(BUSINESS
WIRE)--eFoodSafety.com, Inc. (OTCBB: EFSF, www.efoodsafety.com), a researcher,
developer, and marketer of whole foods and nutraceutical products, provides
its shareholders with an update on its products and product pipeline.
“This is an exciting
and active time for eFoodSafety as we recently initiated a comprehensive
and robust direct-response campaign for two of our products with two more
expected to launch in the coming months,” says Patricia Gruden, CEO of
eFoodSafety. “In the meantime, we continue our research and development
activities for many of our other products. We are committed to focusing
our efforts on those products that we believe have the greatest potential
to address major health concerns in mass markets.”
Ms. Gruden continues,
“With so many products in development and others on the market, we believe
it is a timely occasion to update our shareholders, consumers, and other
interested parties, as to our progress. To facilitate the update, we have
provided information on our lead products in development as well as those
that are currently on the market.”
Lead Products in Research
& Development:
Citroxin™: Most recently,
Citroxin was tested for its ability to eradicate the H5N1 strain of the
bird flu in chick embryos. The test, conducted at Chulalongkorn University
in Thailand, showed 68% efficacy. Based on the success of this initial
study, the company will initiate a next round of testing in live animals
with forms of flu that closely resemble human strains of the disease. These
tests will be conducted at a university in the United States that is nationally
recognized for its field studies in bird flu.
According to the World
Health Organization, there have been 241 deaths in humans in 382 reported
cases of the H5N1 strain of avian influenza worldwide from 2003 to the
present. In addition to the human implications of the virus, bird and farm
animals are also at risk from infection. As an early entrant in the market,
eFoodSafety recognizes potential to use its formula in the mass market
as a solution against the virulent influenza.
--
Citroxin O2™: eFoodSafety’s
researchers have completed the EPA required testing against the six major
bacteria: (E-coli, Listeria, Pseudomonas, Salmonella, Staphylococcus, and
Streptococcus), as well as the H95N strain of avian influenza. Citroxin
O2 is currently being tested on chick embryos at Chulalongkorn University
in Thailand.
--
Proxorin™: Clinical testing
has been initiated for its use as a natural antibiotic/anti-microbial against
common bacterial pathogens. This testing is being conducted at a major
U.S. university, and the company plans to initiate clinical trials on the
formula to determine its efficacy in three to six months. The formula is
derived from Citroxin, but differs in its time-release capabilities, which
allow it to more effectively deliver its ingredients throughout the body.
As a natural alternative,
Proxorin can offer several advantages over common drug-based antibiotics,
which dominate the large market. As the company continues to advance the
R&D process for this formula, it expects to create various forms of
the product, including a trans-dermal cream and a high-potency pill for
oral ingestion.
--
Occusyn™: Informal human
case studies have indicated that Occusyn, an integral component of the
company’s proprietary Lyme disease protocol, has demonstrated 100% efficacy
against Lyme disease. The company plans to initiate additional human clinical
trials within the next six to nine months. Lyme disease costs society approximately
$1 billion in direct and indirect costs per year. With antibiotics currently
the treatment of choice for the disease, the company hopes to offer new
all-natural advantages to the market in an effort to combat the disease.
--
OraPhyte™: U.S. Department
of Agriculture tests have shown OraPhyte to be effective at eradicating
nematodes, a parasite commonly found in freshwater, marine, and terrestrial
environments that are known to be harmful to plants. Three major U.S. universities
have conducted year-long agricultural studies on the product, and after
their positive experiences in treating nematodes affecting plants or food
crops, they have decided to continue testing. Furthermore, a fourth major
university will also begin testing the product within its agricultural
department undergoing crop-specific research.
Crop damage attributable
to nematodes accounts for significant economic losses in the multi-million
dollar range. The purpose of the additional testing is to refine the product
and further identify specific uses. The licensing agreement can then be
use-specific. The company has been informed that the testing should be
completed within the next 3-4 months and anticipates that one or more licensing
agreements may be finalized before year-end.
“In addition to our intensive
R&D efforts, eFoodSafety has gained significant traction on the marketing
front,” Ms. Gruden adds. “We recently launched two direct-response campaigns,
a dramatic accomplishment, as we mobilize from an R&D company to an
R&D company that also markets its products to consumers.”
Products Available to
Consumers or Nearing Retail Launch:
--
Cinnergen™: The company
recently launched a direct-response marketing campaign for Cinnergen™ with
Respond2 Communications Inc, a leading direct-response agency. The two
companies will continue to refine the campaign to achieve maximum results
and audience exposure. Shareholders can view the campaign at www.cinnergendirect.com.
According to the American Diabetic Association, the annual economic impact
of diabetes is over 170 Billion dollars annually. Cinnergen presents another
option for consumers to help regulate blood sugar levels.
--
Cinnechol™: Cinnechol’s
direct-response marketing campaign also recently launched. The commercial
can be viewed at www.cinnechol.com. eFoodSafety continues to work with
Respond2 Communications to maximize the effectiveness of the campaign.
Given the market pressure on prescription drugs that have come under scrutiny
for potential side effects, the company believes that consumers may be
increasingly apt to try all-natural solutions as an alterative.
The results to date of
the direct-response campaigns have shown an initial moderate increase in
product sales. Review of the data collected to date has indicated that
the number of visitors to the respective internet sites from the commercials
has far exceeded expectations. However, the company and Respond2 are making
additional modifications to the campaigns to bring about a higher conversion
of sales with respect to both internet and call volume received.
--
NumaDerm™: In another
important development, the company expects the NumaDerm direct-response
campaign to launch in the next 1-2 months. The product targets a mass consumer
base, and its broad appeal is expected to help the company gain additional
traction in its sales.
--
PurEffect™: PurEffect
will soon be available to consumers through a direct-response marketing
campaign that will include celebrity endorsements. As a four-step treatment
process for acne, the product provides a front- to back-end solution.
--
Immune Boost Bars™: ImmuneBoost
Bars are currently available online at www.immuneboost.com. Through the
company’s relationship with CPG Focus Consulting, it is in discussions
with major national retailers to expand its market presence.
--
Talsyn™: Talsyn is currently
available to patients through physicians. eFoodSafety has also incorporated
Talsyn’s formula in some of its other products, such as PurEffect and NumaDerm,
to serve as a complement to help repair scarring.
“It is important to highlight
that we are committed to growing and advancing our business as a whole,
including both the R&D processes as well as the consumer rollout of
our products,” concludes Ms. Gruden. “For a company the size of ours to
successfully develop, manage, and market such a large and varying suite
of products, serves as an indication of the scope of our capabilities and
pledge to continue driving growth. We look forward to continuing to update
our valued shareholders on a regular basis.”
About eFoodSafety.com
eFoodSafety.com, Inc.,
based in Scottsdale, Arizona, is dedicated to improving health conditions
around the world through its innovative technologies. Among eFoodSafety
products currently available:
Citroxin™: an environmentally
safe sporicidal product formulated entirely of food-grade components that
kills six major bacteria as well as avian influenza.
Cinnergen™: a clinically
researched, non-prescription liquid whole food nutritional supplement that
promotes healthy glucose metabolism.
Cinnechol™: a multi-faceted
nutritional supplement specifically designed to naturally promote healthy
cholesterol and triglyceride levels without causing any side effects, as
well as enhance overall cardiovascular health.
PurEffect™: an anti-acne
skin care system.
Immune Boost Bar™: a
non-dairy, no refined sugar, all-natural and comprehensive multi-nutrient
product that helps fortify the body’s immune system and is available in
four delicious flavors: chocolate, oatmeal-raisin, chocolate mint and peanut
butter.
Talsyn™: a product that
has been clinically proven to facilitate and improve the appearance, redness
and strength of scars.
Please visit the company’s
website at: http://www.efoodsafety.com.
Safe Harbor Forward-Looking
Statements
Statements contained
in this release that are not strictly historical are “forward-looking statements.”
Such forward-looking statements are sometimes identified by words such
as “intends,” “anticipates,” “believes,” “expects,” and “hopes.” The forward-looking
statements are made based on information available as of the date hereof,
and the Company assumes no obligation to update such forward-looking statements.
Editors and investors are cautioned that such forward-looking statements
involve risks and uncertainties that could cause the Company’s actual results
to differ materially from those in these forward-looking statements. Such
risks and uncertainties include but are not limited to demand for the Company’s
products and services, our ability to continue to develop markets, general
economic conditions, our ability to secure additional financing for the
Company and other factors that may be more fully described in reports to
shareholders and periodic filings with the Securities and Exchange Commission.
Contact:
Redwood Consultants,
LLC
Jens Dalsgaard, 415-884-0348
or
The Investor Relations
Group
212-825-3210
Investor Relations:
Michael Crawford
mcrawford@investorrelationsgroup.com
or
Emily Hanan
ehanan@investorrelationsgroup.com
or
Media Relations:
Susan Morgenbesser
smorgenbesser@investorrelationsgroup.com
or
Lynn Granito
lgranito@investorrelationsgroup.com
Source: eFoodSafety.com,
Inc. |
Free Annual Reports
